Telpart-H

COMPOSITION

Telpart-H Tablets

Each tablet contains: Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg

INDICATIONS

ducts Fr **Hypertension** This fixed dose combination is not indicated for initial therapy

DOSAGE AND ADMINISTRATION

The usual initial dosage is one tablet of TELPART-H TABLETS daily. A patient whose blood pressure is not adequately controlled with telmisartan monotherapy 40 mg may be switched to TELPART-H TABLETS. The dose may be increased, if necessary, to two tablets of TELPART-H TABLETS .

A patient whose blood pressure is not adequately controlled with hydrochlorothiazide 25 mg once daily may be switched to TELPART-H TABLETS .

Patients with depletion of intravascular volume should have the condition corrected or telmisartan tablets should be initiated under close medical supervision.

Patients with Renal Impairment

The usual regimens of therapy with TELPART-H TABLETS may be followed as long as the patient's creatinine clearance is more than 30 mL/min. In patients with more severe renal impairment, TELPART-H TABLETS is not recommended.

Patients with Hepatic Impairment

TELPART-H TABLETS is not recommended for patients with severe hepatic impairment. Patients with biliary obstructive disorders or hepatic impairment should have treatment started with TELPART-H TABLETS under close medical supervision.

CONTRAINDICATIONS

TELPART-H TABLETS is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, hydrochlorothiazide, or any other component of this product. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

PACKAGING INFORMATION

Ruality Products From TELPART-H TABLETS ALu-ALu pack of 10 tablets